www.globalbsg.
com
PHARMA AI SUMMIT
HOW WILL ARTIFICIAL INTELLIGENCE
IMPACT THE PHARMACEUTICAL INDUSTRY?
19th - 20th September 2019 | London, UK
KEY PRACTICAL LEARNING POINTS OF THE SUMMIT
• Understanding the role of artificial intelligence
in the pharmaceutical industry
• Showcasing the Utility of AI in early stages
of R&D to Prove This Disruptive Technology’s
Validity
• Introduction to AI applied to chemistry
• How a combination of artificial intelligence,
physics, and chemistry is accelerating drug
discovery: a case study
• AI and the clinical trial design and optimiza-
tion opportunities
• Predicting clinical trial results using deep
learning and electronic health records
• AI as a journey, not a destination: a learning
process
• Increasing Diversity in Peptide Discovery Us-
ing Artificial Intelligence 
• Adjusting pharmaceutical business models to
incorporate AI technologies
• AI in Pharma and Drug Discovery Industry
Landscape  Networks and New Chemical
Entities: Application of Network-driven Drug
Discovery (NDD) in Lead Generation
• Drug discovery, strategic thinking and the
Centaur Chemist
• Modernising the data platform and innovation
• AI linked with IoT enable “smart” Digital as-
sistants opening new possibilities for Drug
Development
www.globalbsg.com
speakers
Chairperson
Yide Alan Jiang
Chief Strategy Officer at XTalPi
Pingping NI
Director, Head of Statistics
and Programming at
Mundipharma Research Ltd
Amit Michaeli
Founder and Chief Technology
Officer at Pepticom
Dr. Sree Vadlamudi
Business Development &
Programme Manager at
E-Therapeutics
Don Van Dyke
Chief Operating Officer at
Cloud Pharmaceuticals
Rosangela Sanches
South America IT Data &
Analytics Lead at Bayer
Nicolas Do Huu & Quentin
Perron
Co-Founder and Chief
Technology Officer, Co-
Founder and Chief Strategy
Office at Iktos
Ketan Patel
Product Director- Portfolio,
Licensing and Clinical at
Clarivate Analytics
Willem Van Hoorn
Chief Decision Scientist at
Exscientia
Isabelle de Zegher
Founder at BeeLoba
Dmitry Kaminskiy
General Partner at Deep
Knowledge Ventures
Alessandro Forlin
Worldwide Associate Brand
Director at Novartis Pharma
AG
Qi Tang
Associate Director of Digital
and Data Sciences at Sanofi
Raymond Hounon
Data & Artificial Intelligence
Business Manager at Microsoft
Murat Tunaboylu
Co-Founder, Director
at Antiverse
Larry Pickett
Former CIO at Purdue
Pharma, current CEO
at RxDataScience at
RxDataScience
www.globalbsg.com

DAY 1 | 19th of September, 2019

08:20 Registration and Welcome Coffee

08:50 Opening Address from the Chairman

09:00 SPEED NETWORKING

THE ROLE OF AI IN THE PHARMACEUTICAL INDUSTRY

09:20 Case Study | Showcasing the Utility of AI in early stages of R&D to Prove This Disruptive
Technology’s Validity
• Developing validated methods to showcase applicability of AI platforms
• Building a “disease-profile” and harnessing multi-object optimization tools to design best
candidates
• Matching AI performance to human decision making to demonstrate the utility of AI
platforms
Don Van Dyke | Chief Operating Officer | Cloud Pharmaceutical

10:00 Case Study | Introduction to AI applied to chemistry

• real life case study presentation in collaboration with Servier
A
• Accelerating the identification of compounds meeting MPO target product profile
• The application of deep generative models
• Opening on other applications of AI in chemistry
Nicolas Do Huu & Quentin Perron | Co-Founder and Chief Technology Officer, Co-Founder and Chief
Strategy Office | Iktos

10:40 MORNING COFFEE BREAK

11:20 Case Study | AI as a journey, not a destination: a learning process

• What AI really is
• How a journey on AI looks like
• Key points to overcoming barriers along this journey
Rosangela Sanches | South America IT Data & Analytics Lead at Bayer | BR, Bayer

12:00 Case Study | C-Level AI Strategy and Technology for Drug Development
• Elements of an AI strategy
• How to accelerate drug development with AI
• AI case study- Quantitative Systems Pharmacology (QSP)
• AI use cases & business outcomes
• AI technology alternatives
Larry Pickett | Former CIO at Purdue Pharma, current CEO at RxDataScience | RxDataScience

12:40 BUSINESS LUNCH

13:50 Case Study | Predicting clinical trial results using deep learning and electronic health
records
• Predicting Phase 3 clinical trial results is a critical step of Go/No-Go decision making and
Phase 3 trial design optimization.
• We proposed a framework consisted of three models, an enrolment model, an individual
trough concentration (Ctrough) model and an individual treatment effect model combined
together to predict Phase 3 trial results using deep learning methods. 
• A successful case study will be presented.
Qi Tang | Associate Director of Digital and Data Sciences | Sanofi
www.globalbsg.com

DAY 1 | 19th of September, 2019

AI AND DRUG DISCOVERY AND DEVELOPMENT

14:30 Case Study | AI and the clinical trial design and optimization opportunities
• Challenges in trial design, and where AI can help
• A framework to incorporate AI into design consideration
Pingping NI | Director, Head of Statistics and Programming | Mundipharma Research Ltd

15:10 AFTERNOON COFFEE BREAK

15:40 Case Study | Networks and New Chemical Entities: Application of Network-driven Drug
Discovery (NDD) in Lead Generation
• etwork-driven Drug Discovery (NDD) platform and process
N
• Applying data augmentation to NCE discovery
• Identifying and optimising unique NCEs in Immuno-oncology
Dr. Sree Vadlamudi | Business Development & Programme Manager | E-Therapeutics

16:20 Case Study | Antiverse

• I in antibody & nanobody drug discovery
A
• Impediments for AI companies in the drug discovery and development space: data &
talent acquisition
Murat Tunaboylu | Co-Founder, Director | Antiverse

17:00 PANEL DISCUSSION | CHALLENGES TO AI IMPLEMENTATION AND ADOPTION

• trategy of reskilling internal workers vs hiring external workers for the implementation
S
of AI
• Collaboration across functions for AI implementation
• Low hanging fruits in AI application to Pharma
• How AI can be leveraged within Internal Audit in Pharma?
Moderator:
Ketan Patel | Product Director- Portfolio, Licensing and Clinical | Clarivate Analytics
Panelists:
Nicolas Do Huu & Quentin Perron | Co-Founder and Chief Technology Officer, Co-Founder and Chief
Strategy Office | Iktos
Rosangela Sanches | South America IT Data & Analytics Lead at Bayer | Bayer
Murat Tunaboylu | Co-Founder, Director | Antiverse
Dr. Sree Vadlamudi | Business Development & Programme Manager | E-Therapeutics
Larry Pickett | Former CIO at Purdue Pharma, current CEO at RxDataScience | RxDataScience

17:30 Chairman’s Closing Remarks and End of Day One

www.globalbsg.com

DAY 2 | 20th of September, 2019

08:20 Registration and Welcome Coffee

08:50 Opening Address from the Chairman

09:00 Case Study | How a combination of artificial intelligence, physics, and chemistry is
accelerating drug discovery: a case study
• Effectively harnessing HPC cloud resources for drug discovery
• How AI-powered crystal structure prediction can disrupt the pharmaceutical industry
• Protecting data while leveraging shared, cloud-based HPC resources
• How highly accurate computations can help companies save money, save time, and lower
risk across all phases of drug development
Yide Alan Jiang | Chief Strategy Officer | XTalPi

09:40 Case Study | Drug discovery, strategic thinking and the Centaur Chemist
• Trajectory of hit to candidate is the most expensive part of drug discovery
• Exscientia has successfully combined AI tech with human strategic thinking into the
Centaur ChemistTM
• The Centaur ChemistTM has delivered multiple clinical candidates in less than a year 
Willem Van Hoorn | Chief Decision Scientist | Exscientia

10:20 Case Study | Increasing Diversity in Peptide Discovery Using Artificial Intelligence 
• The chemical space challenge in peptide discovery, and the method to address it.
• Example of AI discovered bi-specific cyclic peptides for immune modulation.
• Increasing diversity via incorporation of non-natural sub units.
• Examples of effects in Immune modulation and ion channel inhibition projects. 
• The future market impacts of AI discovery.
Amit Michaeli | Founder and Chief Technology Office | Pepticom

11:00 MORNING COFFEE AND NETWORKING BREAK

11:30 Case Study | The importance of predictive analytics to drug time and success rates
• Machine learning is applied to identify paths and time to approval for drug development
programs
• Predictions are generated for each drug development project considering the impact of
each aspect of the project
• An expansive set of historical and current data can be pulled into the model
• Results are based on quantifiable, data-driven evidence derived from extensive data
preparation and statistical modelling.
Ketan Patel | Product Director- Portfolio, Licensing and Clinical | Clarivate Analytics
www.globalbsg.com

DAY 2 | 20th of September, 2019

STRATEGIC IMPLICATIONS IN TIMES OF DISRUPTIVE INNOVATION

12:10 PANEL DISCUSSION | Future approach to Pharma AI

• ow will AI transform Drug Development?
H
• Are futuristic approaches like the one from Neuralink – realistic
• Power of AI in breaking down silos by integration of different modality of data into deep
learning models
Moderator:
Ketan Patel | Product Director- Portfolio, Licensing and Clinical | Clarivate Analytics
Panelists:
Willem Van Hoorn | Chief Decision Scientist | Exscientia
Yide Alan Jiang | Chief Strategy Officer | XTalPi
Isabelle de Zegher | Founder | BeeLoba
Raymond Hounon | Data & Artificial Intelligence Business Manager | Microsoft

12:50 Business Lunch

13:50
Case Study | AI in Pharma and Drug Discovery Industry Landscape 
• I-companies, Investment Funds, Pharma corporations, IT and Tech corporations
A
• Industry Technological and Financial forecasting for 2019-2020
Dmitry Kaminskiy | General Partner | Deep Knowledge Ventures

14:30 Case Study | AI linked with IoT enable “smart” Digital assistants opening new
possibilities for Drug Development
• I ntegration of IoT and AI technologies into a patient-centric digital platform
• New approaches to trial execution
• New generation of pharma products toward mHealth. 
Isabelle de Zegher | Founder | BeeLoba

15:10 AFTERNOON COFFEE BREAK

15:30 Case Study | Modernising the data platform and innovation

• nalytics capabilities and insights
A
• Automating business processes by leveraging new data analytics tools and Artificial
intelligence solutions
Raymond Hounon | Data & Artificial Intelligence Business Manager | Microsoft

16:10 Case Study | Pharma marketing challenges and how AI solutions can help
• ollective intelligence and possible initiatives for marketing
C
• Solutions for analysis, planning, execution- how to address key needs along the patient
pathway
• How to drive an effective implementation of AI solutions (driving culture, C-level
endorsements)
Alessandro Forlin | Worldwide Associate Brand Director | Novartis Pharma AG

17:00 CHAIRMAN’S CLOSING REMARKS AND END OF SUMMIT

www.globalbsg.com
Yide Alan Jiang
Chief Strategy Officer at XTalPi
Entrepreneurial Board Director, Co-founder, Executive, Industrial
advisor and Investor
Dr. Jiang as Chief Strategy Officer, Board Director of XtalPi, bears
primary responsibility for the company’s strategy development
including identification of growth opportunities, strategic planning
and execution. He joined Xtalpi in 2015 bringing over fifteen years
of scientific and research management experience. Dr. Jiang
was previously the director of Asia R&D Strategy of the Sanofi-
Genzyme R&D Center and in that capacity, he was responsible for
the development of Genzyme Asia/China R&D strategy and led
cross-functional R&D external collaborations and projects in Asia.
Dr. Jiang received his medical degree and doctorate in molecular
biology followed by post-doctoral research in hematology and
oncology at Brigham & Women’s Hospital, Harvard Medical School.
Willem Van Hoorn
Chief Decision Scientist at
Exscientia
Willem van Hoorn gained a MSc in Chemical Engineering and a
PhD in computational chemistry at the University of Twente, the
Netherlands followed by a postdoc at Yale with Bill Jorgensen.
He subsequently spent a decade at Pfizer Sandwich focusing on
computational techniques for HTS triage and combinatorial library
design. This was followed by a position as IT consultant at Accelrys
(now Biovia) assisting a range of clients from small biotech to big
pharma. Since 2013 he is pursuing his long term interest of applying
computer algorithms to drug discovery at Exscientia  regression trees, a classical machine learning method. Provisional
Pingping NI
Director, Head of Statistics and
Programming at Mundipharma
Research Ltd
Isabelle de Zegher
Founder at BeeLoba
Isabelle de Zegher, MD, MS, is Founder of BeeLoba, focusing on
patient data sharing solutions.  She  used to be Vice President,
Integrated Solutions at PAREXEL Informatics,  focusing on Big
Data, Data Standards, AI and digital solutions.  She worked for 10
years at PAREXEL and  14 years  in pharma clinical development
including Novartis, UCB and Cap Gemini Life Sciences consulting.
Before that she worked for 10 years in Health Care IT at Cap
Gemini and in a Belgium SME. She has extensive experience in
health information technology, data standards, data integration,
semantic interoperability and application of AI in clinical research.
She chaired the EFPIA task force on EHR integration and served on
the CDISC Board of Directors for 3 years. She co-chaired the PhUSE
- FDA CSS working group on Emerging technology and served as
chair or co-chair in many conferences.
BIOGRAPHIES
Don Van Dyke
Chief Operating Officer at Cloud
Pharmaceuticals
Don Van Dyke is Chief Operating Officer at Cloud Pharmaceuticals. In
his early career, he held increasingly responsible general
management, business development, and  executive positions at
American Hospital Supply,  Dade Diagnostics,  Eastman Kodak and
Millipore Corporation.
Van Dyke’s work at the intersection of biological science and
computer science began at startup Bio Image Corporation. The
company became market leader in image-based genomics and
proteomics under his leadership as VP sales, VP worldwide
marketing and sales, general manager, and CEO.
He has had  executive  roles at Molecular Mining Corporation, a
life science data mining company and INCOGEN, a Bioinformatics
company  and has advised more than a dozen start-ups and
government agencies.
Qi Tang
Associate Director of Digital and
Data Sciences at Sanofi
Dr. Tang graduated from University of Wisconsin with PhD in
statistics in 2010 and has eight years plus of clinical phase drug
development experience. He has chaired an AI journal club in Sanofi
since 2017 and has given two short courses on AI and its application
to clinical data analytics in professional conferences. He has
successfully applied AI methods to prediction of individual patient’s
PK concentration and efficacy and safety outcomes and made
AI explainable by opening the black box using classification and
patents have been filed for some of his work in application of AI to
the medical field.
Rosangela Sanches
South America IT Data & Analytics
Lead at Bayer
With strong knowledge on data & analytics space and academic
background on business and IT, Rosangela Sanches has implemented
global and regional projects for large and diversified companies in
a wide-variety of industries to enable new technologies adoption,
advising and supporting then on designing the future data state.
Currently in a journey to enable data strategy for Pharma and Crop
Science in a combined way.
Raymond Hounon
Data & Artificial Intelligence
Business Manager at Microsoft
www.globalbsg.com
Amit Michaeli
Founder and Chief Technology
Officer at Pepticom
“Growing up as the son of a physician during the internet age, I
felt a constant frustration at the slow entrance of computational
searches into the pharmaceutical field. While computers aided
humanity towards reaching unprecedented efficiency in everyday
tasks, like purchasing electronics or ordering lunch, it wasn’t quite
there where we needed it most – finding cures for diseases! I made
it my life mission to give computers the ability to discover peptide
drugs. Together with Prof. Amiram Goldblum and Dr. Immanuel
Lerner, I founded Pepticom, an A.I. peptide drug discovery platform.
With discovered active peptides in numerous fields, we are getting
closer than ever to achieving this dream.”
Dmitry Kaminskiy
General Partner at Deep
Knowledge Ventures
Dmitry Kaminskiy is an innovative entrepreneur and investor who
is active in the fields of BioTech, FinTech, BlockChain, Artificial
Intelligence. Kaminskiy is a co-founder and a managing partner
at Deep Knowledge Ventures, an investment fund focused on
DeepTech and advanced science projects.
Dmitry is a frequent speaker on the topics of AI and Longevity.
During the last year he spoke at conferences organized in London
by The Economist “Aging Societies and The Business of Longevity”,
Financial Times “Smart Machines vs Smart People”, and at the
Future Finance Forum in Seoul “AI in Finance”, as well as several
others at Oxford and Cambridge Universities.
Dr. Sree Vadlamudi
Business Development &
Programme Manager at
E-Therapeutics
Sree joined e-therapeutics in 2013 as a Programme Manager to
help in the implementation of the network-driven approach to
drug discovery and was subsequently promoted to the Business
Development and Programme Manager role. He  is a medicinal
chemist by training with over 14 years’ experience in the
Biotechnology industry. He has a track record in leading projects
from inception to lead generation and optimisation, and is a named
author on multiple patents and publications. Sree is responsible
for business development activities to maximize collaborations and
licensing opportunities with bio-pharma organizations,  programme
management activities to enable delivery of multiple projects on
time and within budgets.
Alessandro Forlin
Worldwide Associate Brand
Director at Novartis Pharma AG
Alessandro is International marketing leader with over 13 years
of successful strategic and operational pharmaceutical marketing
career at Global, Region and Country level, working in different
therapeutic areas for companies such as Lilly, Menarini and Novo
Nordisk. More recently he joined Novartis Pharma AG at company
headquarter in Basel with the role as WorldWide Associate Brand
Director in the Rheumatology area and actively collaborating with
the Digital Solutions Team. He is passionate about bringing AI
solutions into pharma marketing and has a foresight view about
how pharma marketing can evolve thanks to AI.
BIOGRAPHIES
Nicolas Do Huu
Co-Founder and Chief Technology
Officer, Co-Founder and Chief
Strategy Office at Iktos
An accomplished data scientist and R&D engineer with proven
expertise in Deep Learning algorithms with an extensive experience
in machine learning, big data analysis and software optimization
in distributed environments. A swiss army knife profile able to fill
the gap between state-of-the-art theories and fast and scalable
solutions with user-friendly interfaces as a bonus.
Murat Tunaboylu
Co-Founder, Director
at Antiverse
Software Engineer/Bioinformatician with 13 years of professional
experience. Mid-career, he has worked in finance and developed
high-frequency trading systems. After switching to biotech he has
built cell imaging software and lab robots for acceleration of cancer
research and automated Thermo Fisher Scientific’s gene synthesis
workflows. He has co-founded consultancy and biotech companies
Svarlight and Antiverse. Currently, he is developing machine
learning models at Antiverse to speed up drug discovery.
Ketan Patel
Product Director- Portfolio,
Licensing and Clinical at Clarivate
Analytics
Ketan’s background spans 15 years of experience working in industry
at Lilly, Pfizer, Oracle HSGBU and most recently at Astrazeneca.
Over the years Ketan has led and worked on data science projects
in the industry from early stage drug discovery through to clinical
development, product launch and medical affairs. More recently
he was a Health informatics Director working on Big Health data
(claims, EHRs, digital, genomics etc.) for AZ to optimise clinical trials,
product launch and post-marketing and life cycle management
Larry Pickett
Former CIO at Purdue Pharma,
current CEO at RxDataScience at
RxDataScience
Larry A Pickett, Jr is co-founder and CEO of RxDataScience Inc., a
data science company focused on healthcare and life sciences. 
He has 30 year’s experience in the pharmaceutical industry in IT
in executive roles such as Chief Information Officer for companies
such as Merck, GSK and Purdue Pharma.  Larry earned his BA and
MBA from the University of North Carolina at Chapel Hill.    Larry
enjoys working with his clients to leverage data using AI and ML to
improve business results in a predictive and reliable manner.
Quentin Perron
Co-Founder and Chief Strategy
Officer at Iktos
Co-founder and CSO of Iktos, Quentin Perron holds a PhD in organic
chemistry from U. Geneva and a postdoc in total synthesis at UCLA.
He is an expert in chemoinformatics. He is the co-inventor of Iktos
original de novo design algorithm and supervises R&D and project
delivery.
www.globalbsg.com

REGISTRATION FORM

Title: Title:

Name: Name:

Possition: Possition:

Email: Email:

Phone: Phone:

Title: Title:

Name: Name:

Possition: Possition:

Email: Email:

Phone: Phone:

Organization:

Address:

City:

VAT No: Postcode:

Fax: Phone:

Signature: Date:
This booking is invalid without signature

PRICES
Delegate package + VAT Solution Provider and Vendor + VAT Online documentation
1,699€ 1,999€ 499€

Card No:

Card Holder:

Expiration:

Billing Address:

City: Postcode:

CVV:
If you haven’t recieved a registration corfimation within 48 hours of registering, please call +420 210 022 063

daniel.holm@globalbsg.com Phone: +420 210 022 063 Fax your booking to: + 420 234 256 231

Payment Terms: Full payment is required within five (5) business days of the return of the signed registration form.
A confirmation letter and invoice will be sent on receipt of your booking. If you do not receive a letter outlining
details two weeks prior to the event, please contact the Conference Director at Business Solution Group. Cancel-
lations: Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must
be received in writing no less than fourteen (14) days prior to the event. You would then be issued a credit note
for 100% of the contract fee paid to be used at another Business Solution Group event, which must occur within
one year from the date of issuance. In the event that Business Solution Group cancels or postpones an event for
any reason, the delegate will receive a credit note for 100% of the contract fee paid. In the event that Business
Solution Group postpones
an event for any reason and the delegate is unable or unwilling to attend on the rescheduled date, the delegate
will receive a credit note for 100% of the contract fee paid. You may use this credit for another Business Solution
Group event, which must occur within one year from the date of cancellation or postponement. Except as specified
above, no credits will be issued for cancellations.
There are no refunds given under any circumstances. Non-payment or non-attendance does not constitute cancel-
lation. The booking fee does not include accommodation or travel costs; these are the responsibility of the Dele-
gate. It may be necessary for reasons beyond the control of Business Solution Group to alter the content, timings
or venue. Business Solution Group is not responsible for any loss or damage as a result of a substitution, alteration,
or cancellation/ postponement of an event. Business Solution Group shall assume no liability whatsoever in the
event this conference is cancelled, rescheduled or postponed due to a fortuitous event, Act of God, unforeseen
occurrence or any other event that renders performance of this conference impracticable, illegal or impossible.
Please note that while speakers and topics were confirmed at the time of publishing, circumstances beyond the
control of Business Solution Group may necessitate substitutions, alterations or cancellations of the speakers and/
or topics. As such, Business Solution Group reserves the right to alter or modify the advertised speakers and/or
topics if necessary without any liability to you whatsoever.
The full T&C is available on our website - www.globalbsg.com
 Politickych Veznu 912/10,
Nove Mesto. 110 000 Praque 1,
Czech Republic

+420 210 022 063

info@globalbsg.com